Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades! - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36051422/
Several pharmacological agents to prevent the progression of diabetic kidney disease (DKD) have been tested in patients with type 2 diabetes mellitus (T2DM) in the past two decades. With the...
Conclusions: Similar positive findings on renal outcomes were recently reported as a top-line result of the empagliflozin trial in patients with CKD regardless of T2DM. However, the full results of this trial have not yet been published. While the use of older steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone in DKD...
PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36027111/
Currently, it's not well known what factors influenced the incidence of heart failure with preserved ejection (HFpEF) fraction in patients receiving sodium glucose co-transporter 2 inhibitors (SGLT2i). Objective: To evaluate...
Conclusions: Predictors for incidence HFpEF in patients with T2DM were age, diabetes duration, presence of abdominal obesity and galectin-3 levels higher than 10 ng/ml.
IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36026660/
1 Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, GERMANY. 2 Department of Nephrology and Hypertension, Paracelsus Medical University, Nürnberg, GERMANY. 1 Department of Nephrology and Hypertension, University Hospital...
Conclusions: Basal NO emerged as a determinant of the renal hemodynamic response in the combination therapy of empagliflozin and linagliptin, but not in the combination therapy of insulin and metformin.
INFLUENCE OF MEAN OFFICE BLOOD PRESSURE(BP) LEVELS ON MORTALITY IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36026726/
In our study, we did not observe differences in mortality between patients with low normal or high SBP, neither on those with high, normal nor low DBP. Although there may...
Conclusions: In our study, we did not observe differences in mortality between patients with low normal or high SBP, neither on those with high, normal nor low DBP. Although there may be a selection bias and this is a retrospective study, more studies are needed to assess the influence of BP control on the evolution of HFpEF in octogenarian...
Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.956041/full
BackgroundEmpagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin on...
Conclusion: Empagliflozin significantly reduces serum-induced proliferation and migration of SMCs in vitro and prevents neointima formation in vivo, while augmenting EC proliferation in vitro and re-endothelialization in vivo after vascular injury. These data document the functional impact of empagliflozin on vascular human SMCs and ECs and...